<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39195858</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2226-4787</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Pharmacy (Basel, Switzerland)</Title><ISOAbbreviation>Pharmacy (Basel)</ISOAbbreviation></Journal><ArticleTitle>Evaluating the Risk-Benefit Profile of Corticosteroid Therapy for COVID-19 Patients: A Scoping Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">129</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmacy12040129</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The 2019 coronavirus (COVID-19) outbreak was declared a global pandemic in March 2020. It quickly spread across all continents, causing significant social, environmental, health, and economic impacts. During the pandemic, there has been consideration of repurposing and repositioning of medications, such as corticosteroids, for the treatment of hospitalised COVID-19 patients.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess and summarise corticosteroid regimens used for hospitalised COVID-19 patients, focusing on dosage, route of administration, and clinical outcome from clinical trials.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed and Embase databases and the grey literature were searched to identify randomised controlled trials (RCTs) that evaluated the efficacy of corticosteroids in hospitalised patients with COVID-19 between January 2020 and January 2023. This scoping review was conducted in line with the PRISMA extension for scoping reviews (PRISMA-ScR) checklist.</AbstractText><AbstractText Label="KEY FINDINGS" NlmCategory="RESULTS">A total of 24 RCTs were eligible for inclusion. There was variation in the steroid regimens used for treatment across COVID-19 trials. Despite the heterogeneity of included RCTs, the overall results have shown the benefits of improving lung function and a lower all-cause mortality rate in hospitalised COVID-19 patients treated with systematic corticosteroids.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Corticosteroids have proven to be an effective treatment for COVID-19 patients in critical condition. However, comparative effectiveness studies should be conducted to assess the efficacy and safety of optimal corticosteroid treatment at the population level. Moreover, the global burden of long COVID is significant, affecting millions with persistent symptoms and long-term health complications. Thus, it is also necessary to evaluate the optimal steroid regimen for long COVID treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Daniel Hsiang-Te</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0003-2841-0338</Identifier><AffiliationInfo><Affiliation>Centre for Neonatal and Paediatric Infection, St George's University of London, London SW17 0RE, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harmon</LastName><ForeName>Emma</ForeName><Initials>E</Initials><Identifier Source="ORCID">0009-0006-3993-7556</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Queens University Belfast, Belfast BT9 7BL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goelen</LastName><ForeName>Jan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6796-3210</Identifier><AffiliationInfo><Affiliation>Centre for Neonatal and Paediatric Infection, St George's University of London, London SW17 0RE, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barry</LastName><ForeName>Heather E</ForeName><Initials>HE</Initials><Identifier Source="ORCID">0000-0002-9684-8182</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Queens University Belfast, Belfast BT9 7BL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Li-Yang</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Queens University Belfast, Belfast BT9 7BL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsia</LastName><ForeName>Yingfen</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-7955-852X</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Queens University Belfast, Belfast BT9 7BL, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmacy (Basel)</MedlineTA><NlmUniqueID>101678532</NlmUniqueID><ISSNLinking>2226-4787</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">corticosteroids</Keyword><Keyword MajorTopicYN="N">randomised clinical trial</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>10</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39195858</ArticleId><ArticleId IdType="pmc">PMC11360832</ArticleId><ArticleId IdType="doi">10.3390/pharmacy12040129</ArticleId><ArticleId IdType="pii">pharmacy12040129</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chappell L., Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., et al. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 2021;384:693&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomazini B.M., Maia I.S., Cavalcanti A.B., Berwanger O., Rosa R.G., Veiga V.C., Avezum A., Lopes R.D., Bueno F.R., Silva M.V.A. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX randomized clinical trial. JAMA. 2020;324:1307&#x2013;1316. doi: 10.1001/jama.2020.17021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17021</ArticleId><ArticleId IdType="pmc">PMC7489411</ArticleId><ArticleId IdType="pubmed">32876695</ArticleId></ArticleIdList></Reference><Reference><Citation>Acter T., Uddin N., Das J., Akhter A., Choudhury T.R., Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. Sci. Total Environ. 2020;730:138996. doi: 10.1016/j.scitotenv.2020.138996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scitotenv.2020.138996</ArticleId><ArticleId IdType="pmc">PMC7190497</ArticleId><ArticleId IdType="pubmed">32371230</ArticleId></ArticleIdList></Reference><Reference><Citation>Edalatifard M., Akhtari M., Salehi M., Naderi Z., Jamshidi A., Mostafaei S., Najafizadeh S.R., Farhadi E., Jalili N., Esfahani M. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: Results from a randomised controlled clinical trial. Eur. Respir. J. 2020;56:2002808. doi: 10.1183/13993003.02808-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02808-2020</ArticleId><ArticleId IdType="pmc">PMC7758541</ArticleId><ArticleId IdType="pubmed">32943404</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., Liu S., Zhao P., Liu H., Zhu L. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020;8:420&#x2013;422. doi: 10.1016/S2213-2600(20)30076-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30076-X</ArticleId><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho K.S., Narasimhan B., Difabrizio L., Rogers L., Bose S., Li L., Chen R., Sheehan J., El-Halabi M.A., Sarosky K. Impact of corticosteroids in hospitalised COVID-19 patients. BMJ Open Respir. Res. 2021;8:e000766. doi: 10.1136/bmjresp-2020-000766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjresp-2020-000766</ArticleId><ArticleId IdType="pmc">PMC8023732</ArticleId><ArticleId IdType="pubmed">33811098</ArticleId></ArticleIdList></Reference><Reference><Citation>Soliman O., Moeen S., Abbas Y.A., Kamel E.Z. The impact of dexamethasone versus methylprednisolone upon neutrophil/lymphocyte ratio in COVID-19 patients admitted to ICU and its implication upon mortality. Egypt. J. Anaesth. 2022;38:78&#x2013;84. doi: 10.1080/11101849.2021.2024985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/11101849.2021.2024985</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui X., Chen W., Zhou H., Gong Y., Zhu B., Lv X., Guo H., Duan J., Zhou J., Marcon E., et al. Pulmonary Edema in COVID-19 Patients: Mechanisms and Treatment Potential. Front. Pharmacol. 2021;12:664349. doi: 10.3389/fphar.2021.664349.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.664349</ArticleId><ArticleId IdType="pmc">PMC8215379</ArticleId><ArticleId IdType="pubmed">34163357</ArticleId></ArticleIdList></Reference><Reference><Citation>Toroghi N., Abbasian L., Nourian A., Davoudi-Monfared E., Khalili H., Hasannezhad M., Ghiasvand F., Jafari S., Emadi-Kouchak H., Yekaninejad M.S. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: A three-arm randomized clinical trial. Pharmacol. Rep. 2022;74:229&#x2013;240. doi: 10.1007/s43440-021-00341-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-021-00341-0</ArticleId><ArticleId IdType="pmc">PMC8627167</ArticleId><ArticleId IdType="pubmed">34837648</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033&#x2013;1034. doi: 10.1016/S0140-6736(20)30628-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamaati H., Hashemian S.M., Farzanegan B., Malekmohammad M., Tabarsi P., Marjani M., Moniri A., Abtahian Z., Haseli S., Mortaz E. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. Eur. J. Pharmacol. 2021;897:173947. doi: 10.1016/j.ejphar.2021.173947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.173947</ArticleId><ArticleId IdType="pmc">PMC7885705</ArticleId><ArticleId IdType="pubmed">33607104</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner C., Griesel M., Mikolajewska A., Mueller A., Nothacker M., Kley K., Metzendorf M.-I., Fischer A.-L., Kopp M., Stegemann M. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst. Rev. 2021;8:CD014963. doi: 10.55633/s3me/E012.2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.55633/s3me/E012.2022</ArticleId><ArticleId IdType="pmc">PMC8406706</ArticleId><ArticleId IdType="pubmed">34396514</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvarani C., Massari M., Costantini M., Merlo D.F., Mariani G.L., Viale P., Nava S., Guaraldi G., Dolci G., Boni L. Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial. Eur. Respir. J. 2022;60:2200025. doi: 10.1183/13993003.00025-2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00025-2022</ArticleId><ArticleId IdType="pmc">PMC8971731</ArticleId><ArticleId IdType="pubmed">35361632</ArticleId></ArticleIdList></Reference><Reference><Citation>Brindisi G., De Vittori V., De Castro G., Duse M., Zicari A.M. Pills to think about in allergic rhinitis children during COVID-19 era. Acta Paediatr. 2020;109:2149&#x2013;2150. doi: 10.1111/apa.15462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15462</ArticleId><ArticleId IdType="pmc">PMC7361544</ArticleId><ArticleId IdType="pubmed">32627237</ArticleId></ArticleIdList></Reference><Reference><Citation>van Paassen J., Vos J.S., Hoekstra E.M., Neumann K.M.I., Boot P.C., Arbous S.M. Corticosteroid use in COVID-19 patients: A systematic review and meta-analysis on clinical outcomes. Crit. Care. 2020;24:696. doi: 10.1186/s13054-020-03400-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03400-9</ArticleId><ArticleId IdType="pmc">PMC7735177</ArticleId><ArticleId IdType="pubmed">33317589</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S., Zhou Q., Huang L., Shi Q., Zhao S., Wang Z., Li W., Tang Y., Ma Y., Luo X., et al. Effectiveness and safety of glucocorticoids to treat COVID-19: A rapid review and meta-analysis. Ann. Transl. Med. 2020;8:627. doi: 10.21037/atm-20-3307.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-20-3307</ArticleId><ArticleId IdType="pmc">PMC7290628</ArticleId><ArticleId IdType="pubmed">32566564</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J.A., Murthy S., Diaz J.V., Slutsky A.S., Villar J., Angus D.C., Annane D., Azevedo L.C.P., Berwanger O., Cavalcanti A.B., et al. Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19: A Meta-analysis. JAMA. 2020;324:1330&#x2013;1341. doi: 10.1001/jama.2020.17023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17023</ArticleId><ArticleId IdType="pmc">PMC7489434</ArticleId><ArticleId IdType="pubmed">32876694</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W., Liu Y., Tian D., Wang C., Wang S., Cheng J., Hu M., Fang M., Gao Y. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct. Target. Ther. 2020;5:18. doi: 10.1038/s41392-020-0127-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-0127-9</ArticleId><ArticleId IdType="pmc">PMC7035340</ArticleId><ArticleId IdType="pubmed">32296012</ArticleId></ArticleIdList></Reference><Reference><Citation>Angus D.C., Derde L., Al-Beidh F., Annane D., Arabi Y., Beane A., van Bentum-Puijk W., Berry L., Bhimani Z., Bonten M. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324:1317&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489418</ArticleId><ArticleId IdType="pubmed">32876697</ArticleId></ArticleIdList></Reference><Reference><Citation>Barros C.M.S.S., Freire R.S., Frota E., Rezende Santos A.G., Farias M.E.L., Rodrigues M.G.A., Silva B.M., Prado Jeronimo C.M., Netto R.L.A., Silva Borba M.G. Short-Course of Methylprednisolone Improves Respiratory Functional Parameters after 120 Days in Hospitalized COVID-19 Patients (Metcovid Trial): A Randomized Clinical Trial. Front. Med. 2021;8:758405. doi: 10.3389/fmed.2021.758405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.758405</ArticleId><ArticleId IdType="pmc">PMC8669506</ArticleId><ArticleId IdType="pubmed">34917633</ArticleId></ArticleIdList></Reference><Reference><Citation>Bat&#x131;rel A., Demirhan R., Eser N., K&#xf6;rl&#xfc; E., Tezcan M.E. Pulse steroid treatment for hospitalized adults with COVID-19. Turk. J. Med. Sci. 2021;51:2248&#x2013;2255. doi: 10.3906/sag-2101-243.</Citation><ArticleIdList><ArticleId IdType="doi">10.3906/sag-2101-243</ArticleId><ArticleId IdType="pubmed">33878858</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouadma L., Mekontso-Dessap A., Burdet C., Merdji H., Poissy J., Dupuis C., Guitton C., Schwebel C., Cohen Y., Bruel C. High-dose dexamethasone and oxygen support strategies in intensive care unit patients with severe COVID-19 acute hypoxemic respiratory failure: The COVIDICUS randomized clinical trial. JAMA Intern. Med. 2022;182:906&#x2013;916. doi: 10.1001/jamainternmed.2022.2168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2022.2168</ArticleId><ArticleId IdType="pmc">PMC9449796</ArticleId><ArticleId IdType="pubmed">35788622</ArticleId></ArticleIdList></Reference><Reference><Citation>Corral-Gudino L., Bahamonde A., Arnaiz-Revillas F., G&#xf3;mez-Barquero J., Abad&#xed;a-Otero J., Garc&#xed;a-Ibarbia C., Mora V., Cerezo-Hern&#xe1;ndez A., Hern&#xe1;ndez J.L., L&#xf3;pez-Mu&#xf1;&#xed;z G. Methylprednisolone in adults hospitalized with COVID-19 pneumonia. Wien. Klin. Wochenschr. 2021;133:303&#x2013;311. doi: 10.1007/s00508-020-01805-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00508-020-01805-8</ArticleId><ArticleId IdType="pmc">PMC7854876</ArticleId><ArticleId IdType="pubmed">33534047</ArticleId></ArticleIdList></Reference><Reference><Citation>Corral-Gudino L., Cusacovich I., Mart&#xed;n-Gonz&#xe1;lez J.I., Muela-Molinero A., Abad&#xed;a-Otero J., Gonz&#xe1;lez-Fuentes R., Ru&#xed;z-de-Temi&#xf1;o &#xc1;., Tapia-Moral E., Cuadrado-Medina F., Mart&#xed;n-Asenjo M. Effect of intravenous pulses of methylprednisolone 250 mg versus dexamethasone 6 mg in hospitalised adults with severe COVID-19 pneumonia: An open-label randomised trial. Eur. J. Clin. Investig. 2023;53:e13881. doi: 10.1111/eci.13881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13881</ArticleId><ArticleId IdType="pmc">PMC9538428</ArticleId><ArticleId IdType="pubmed">36169086</ArticleId></ArticleIdList></Reference><Reference><Citation>Dastenae Z.H., Bahadori A., Dehghani M., Asadi-Samani M., Izadi I., Shahraki H.R. Comparison of the effect of intravenous dexamethasone and methylprednisolone on the treatment of hospitalized patients with COVID-19: A randomized clinical trial. Int. J. Infect. Dis. 2022;122:659&#x2013;664. doi: 10.1016/j.ijid.2022.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.07.019</ArticleId><ArticleId IdType="pmc">PMC9270180</ArticleId><ArticleId IdType="pubmed">35817286</ArticleId></ArticleIdList></Reference><Reference><Citation>Dequin P.-F., Heming N., Meziani F., Plantef&#xe8;ve G., Voiriot G., Badi&#xe9; J., Fran&#xe7;ois B., Aubron C., Ricard J.-D., Ehrmann S. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: A randomized clinical trial. JAMA. 2020;324:1298&#x2013;1306. doi: 10.1001/jama.2020.16761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.16761</ArticleId><ArticleId IdType="pmc">PMC7489432</ArticleId><ArticleId IdType="pubmed">32876689</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanei M., Solaymani-Dodaran M., Qazvini A., Ghazale A.H., Setarehdan S.A., Saadat S.H., Ghobadi H., Hoseininia S., Elahikhah M., Samadi A.H. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: A multicenter, randomized, open-label trial. Respir. Res. 2021;22:245. doi: 10.1186/s12931-021-01833-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-021-01833-6</ArticleId><ArticleId IdType="pmc">PMC8441037</ArticleId><ArticleId IdType="pubmed">34526033</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeronimo C.M.P., Farias M.E.L., Val F.F.A., Sampaio V.S., Alexandre M.A.A., Melo G.C., Safe I.P., Borba M.G.S., Abreu-Netto R.L., Maciel A.B.S. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): A randomised, double-blind, phase IIb, placebo-controlled trial. Clin. Infect. Dis. 2020:1&#x2013;35. doi: 10.1093/cid/ciaa1177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1177</ArticleId><ArticleId IdType="pmc">PMC7454320</ArticleId><ArticleId IdType="pubmed">32785710</ArticleId></ArticleIdList></Reference><Reference><Citation>Maskin L.P., Bonelli I., Olarte G.L., Palizas F., Jr., Velo A.E., Lurbet M.F., Lovazzano P., Kotsias S., Attie S., Lopez Saubidet I. High-versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: A multicenter, randomized open-label clinical trial. J. Intensive Care Med. 2022;37:491&#x2013;499. doi: 10.1177/08850666211066799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/08850666211066799</ArticleId><ArticleId IdType="pmc">PMC8926919</ArticleId><ArticleId IdType="pubmed">34898320</ArticleId></ArticleIdList></Reference><Reference><Citation>Munch M.W., Meyhoff T.S., Helleberg M., Kj&#xe6;r M.B.N., Granholm A., Hjorts&#xf8; C.J.S., Jensen T.S., M&#xf8;ller M.H., Hjortrup P.B., Wetterslev M. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: The COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiol. Scand. 2021;65:1421&#x2013;1430. doi: 10.1111/aas.13941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aas.13941</ArticleId><ArticleId IdType="pmc">PMC8441888</ArticleId><ArticleId IdType="pubmed">34138478</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinz&#xf3;n M.A., Ortiz S., Holgu&#xed;n H., Betancur J.F., Cardona Arango D., Laniado H., Arias Arias C., Mu&#xf1;oz B., Quiceno J., Jaramillo D. Dexamethasone vs. methylprednisolone high dose for COVID-19 pneumonia. PLoS ONE. 2021;16:e0252057. doi: 10.1371/journal.pone.0252057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0252057</ArticleId><ArticleId IdType="pmc">PMC8148307</ArticleId><ArticleId IdType="pubmed">34033648</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan S., Nicolau D.V., Jr., Langford B., Mahdi M., Jeffers H., Mwasuku C., Krassowska K., Fox R., Binnian I., Glover V. Inhaled budesonide in the treatment of early COVID-19 (STOIC): A phase 2, open-label, randomised controlled trial. Lancet Respir. Med. 2021;9:763&#x2013;772. doi: 10.1016/S2213-2600(21)00160-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00160-0</ArticleId><ArticleId IdType="pmc">PMC8040526</ArticleId><ArticleId IdType="pubmed">33844996</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjbar K., Moghadami M., Mirahmadizadeh A., Fallahi M.J., Khaloo V., Shahriarirad R., Erfani A., Khodamoradi Z., Gholampoor Saadi M.H. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: A triple-blinded randomized controlled trial. BMC Infect. Dis. 2021;21:337. doi: 10.1186/s12879-021-06045-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06045-3</ArticleId><ArticleId IdType="pmc">PMC8035859</ArticleId><ArticleId IdType="pubmed">33838657</ArticleId></ArticleIdList></Reference><Reference><Citation>Salton F., Confalonieri P., Centanni S., Mondoni M., Petrosillo N., Bonfanti P., Lapadula G., Lacedonia D., Voza A., Carpen&#xe8; N. Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: A randomised controlled trial (MEDEAS) Eur. Respir. J. 2022;61:2201514. doi: 10.1183/13993003.01514-2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01514-2022</ArticleId><ArticleId IdType="pmc">PMC9650195</ArticleId><ArticleId IdType="pubmed">36356972</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang X., Feng Y.-M., Ni J.-X., Zhang J.-Y., Liu L.-M., Hu K., Wu X.-Z., Zhang J.-X., Chen J.-W., Zhang J.-C. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: A multicenter, single-blind, randomized control trial. Respiration. 2021;100:116&#x2013;126. doi: 10.1159/000512063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000512063</ArticleId><ArticleId IdType="pmc">PMC7900459</ArticleId><ArticleId IdType="pubmed">33486496</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473&#x2013;475. doi: 10.1016/S0140-6736(20)30317-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30317-2</ArticleId><ArticleId IdType="pmc">PMC7134694</ArticleId><ArticleId IdType="pubmed">32043983</ArticleId></ArticleIdList></Reference><Reference><Citation>Corral-Gudino L., Bahamonde A., Arnaiz-Revillas F., G&#xf3;mez-Barquero J., Abad&#xed;a-Otero J., Garc&#xed;a-Ibarbia C., Mora V., Cerezo-Hern&#xe1;ndez A., Hern&#xe1;ndez J.L., L&#xf3;pez-Mu&#xf1;&#xed;z G. GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. MedRxiv. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7854876</ArticleId><ArticleId IdType="pubmed">33534047</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal A., Rochwerg B., Lamontagne F., Siemieniuk R.A., Agoritsas T., Askie L., Lytvyn L., Leo Y.-S., Macdonald H., Zeng L. A living WHO guideline on drugs for COVID-19. BMJ. 2020;370:m3379. doi: 10.1136/bmj.m3379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3379</ArticleId><ArticleId IdType="pubmed">32887691</ArticleId></ArticleIdList></Reference><Reference><Citation>Health NIO  COVID-19 Treatment Guidelines: Corticosteroids.  [(accessed on 29 April 2023)];2020  Available online:  https://www.covid19treatmentguidelines.nih.gov/dexamethasone/</Citation></Reference><Reference><Citation>Meduri G.U., Bridges L., Shih M.-C., Marik P.E., Siemieniuk R.A., Kocak M. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: Randomized controlled trial. Intensive Care Med. 2021;42:829&#x2013;840. doi: 10.1007/s00134-015-4095-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-015-4095-4</ArticleId><ArticleId IdType="pubmed">26508525</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri G.U., Siemieniuk R.A.C., Ness R.A., Seyler S.J. Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS. J. Intensive Care. 2018;6:53. doi: 10.1186/s40560-018-0321-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40560-018-0321-9</ArticleId><ArticleId IdType="pmc">PMC6109298</ArticleId><ArticleId IdType="pubmed">30155260</ArticleId></ArticleIdList></Reference><Reference><Citation>Beran A., Ayesh H., Mhanna M., Srour O., Musallam R., Sayeh W., Khokher W., Altorok N., Noori Z., Assaly R. Methylprednisolone May Be Superior to Dexamethasone in COVID-19: A Meta-Analysis of Randomized Controlled Trials. Am. J. Ther. 2022;29:e351&#x2013;e354. doi: 10.1097/MJT.0000000000001507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MJT.0000000000001507</ArticleId><ArticleId IdType="pubmed">35533325</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel N., Goyal N., Nagaraja R., Kumar R. Systemic corticosteroids for management of &#x2018;long-COVID&#x2019;: An evaluation after 3 months of treatment. Monaldi Arch. Chest Dis. 2021;92:2. doi: 10.4081/monaldi.2021.1981.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/monaldi.2021.1981</ArticleId><ArticleId IdType="pubmed">34730322</ArticleId></ArticleIdList></Reference><Reference><Citation>Mal&#xe1;ska J., Sta&#x161;ek J., Du&#x161;ka F., Bal&#xed;k M., M&#xe1;ca J., Hruda J., Vymazal T., Klementov&#xe1; O., Zatloukal J., Gabrhel&#xed;k T. Effect of dexamethasone in patients with ARDS and COVID-19&#x2013;prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22:172. doi: 10.1186/s13063-021-05116-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-021-05116-9</ArticleId><ArticleId IdType="pmc">PMC7917377</ArticleId><ArticleId IdType="pubmed">33648568</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;rhi F., Moonesinghe S.R., Shenkin S.D., Drake T.M., Mulholland R.H., Donegan C., Dunning J., Fairfield C.J., Girvan M., Hardwick H.E., et al. Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: Prospective, cohort study. Lancet Digit. Health. 2022;4:e220&#x2013;e234. doi: 10.1016/S2589-7500(22)00018-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(22)00018-8</ArticleId><ArticleId IdType="pmc">PMC8940185</ArticleId><ArticleId IdType="pubmed">35337642</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>